Oxford Asset Management’s vTv Therapeutics VTVT Stock Holding History

Oxford Asset Management’s Portfolio VTVT Stock Details VTVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,004	Closed	-$106K	–	2014
2018 Q4	$106K	Buy	+1,004	New	+$92.9K	﹤0.01%	1644
2016 Q2	–	Sell	-575	Closed	-$119K	–	885
2016 Q1	$119K	Sell	575 -1,228	-68%	-$306K	﹤0.01%	745
2015 Q4	$492K	Buy	+1,803	New	+$506K	0.01%	674

Other funds holding VTVT

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Oxford Asset Management's VTVT Position: Q1 2019 in Review

Oxford Asset Management sold out of vTv Therapeutics (VTVT) in Q1 2019, closing a stake of 1,004 shares — an estimated $106K sold.

Oxford Asset Management first reported a position in VTVT in Q4 2015 and held it in 3 quarters. The position peaked at $492K in Q4 2015. 21 funds tracked by Wall St. Rank hold VTVT as of Q1 2019.

Oxford Asset Management reported no remaining vTv Therapeutics position as of Q1 2019 after selling out during the quarter.
Oxford Asset Management sold 1,004 vTv Therapeutics shares in Q1 2019, an estimated $106K.
Oxford Asset Management first reported a position in vTv Therapeutics in Q4 2015 and held it in 3 quarters.
Oxford Asset Management's vTv Therapeutics position peaked at $492K in Q4 2015.
21 funds tracked by Wall St. Rank held vTv Therapeutics as of Q1 2019.

Based on Oxford Asset Management's 13F filing for Q1 2019, filed 15 May 2019.